Secondary Hyperparathyrodism in Adult Predialysis and Dialysis Patients

  • Luigi Biancone
  • Gianluca Leonardi
  • Massimo Gai
  • Giuseppe P. Segoloni
Chapter
Part of the Updates in Surgery book series (UPDATESSURG)

Abstract

Following the recommendations in the Kidney Disease Improved Global Outcome (KDIGO) clinical guidelines [1], the mineral and clinical disorders related to the impact of declining renal function on calcium-phosphorus homeostasis, previously known as “renal osteodystrophy”, are today, more appropriately, renamed as chronic kidney disease-mineral and bone disorders (CKD-MBD).

Keywords

Parathyroid Gland Vascular Calcification Secondary Hyperparathyroidism Chronic Kidney Disease Stage Phosphate Binder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Moe S, Druecke T, Cunningham J et al (2006) Definition, evaluation and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcome (KDIGO). Kidney Int 69:1945CrossRefPubMedGoogle Scholar
  2. 2.
    Isakova T, Wahl P, Vargas GS et al (2011) Fibroblast grow factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Slatopolsky E, Robson AM, Elkan I, Bricker NS (1968) Control of phosphate excretion in uremic man. J Clin Invest 47:1865PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Wolf M (2010) Forging forward with 10 burning questions on FGF 23 in kidney disease J Am Soc Nephrol 21:1427–1435CrossRefPubMedGoogle Scholar
  5. 5.
    Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin Am Soc Nephrol 6: 913–921CrossRefGoogle Scholar
  6. 6.
    Tentori F, Blayney MJ, Albert JM et al (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52:519–530CrossRefPubMedGoogle Scholar
  7. 7.
    Alvarez-Ude F, Feest TG, Ward MK et al (1978) Hemodialysis bone disease: correlation between clinical, histological and other findings. Kidney Int 14:68CrossRefPubMedGoogle Scholar
  8. 8.
    Andress DL (2008) Adynamic bone in patients with chronic kidney disease. Kidney Int 73:1345–1354CrossRefPubMedGoogle Scholar
  9. 9.
    Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy in the first decade of new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 26:1368–1376PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Ketteler M, Biggar PH, Liangos O (2013) FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Nephrol Dial Transplant 28:821–825CrossRefPubMedGoogle Scholar
  11. 11.
    Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Raggi P, Boulay A, Chasan-Taber S et al (2002) Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695–701CrossRefPubMedGoogle Scholar
  13. 13.
    Floege J, Ketteler M (2004) Vascular calcification in patients with end stage renal disease. Nephrol Dial Transplant 19(Suppl 5):V59–V66CrossRefPubMedGoogle Scholar
  14. 14.
    Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913–921CrossRefPubMedGoogle Scholar
  15. 15.
    Liabeuf S, Okazaki H, Desjardins L et al (2014) Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? Nephrol Dial Transplant 29:1275–1284CrossRefPubMedGoogle Scholar
  16. 16.
    Tantisattamo E, Han KH, O’Neill WC (2015) Increased vascular calcification in patients receiving warfarin. Arterioscler Thromb Vasc Biol 35:237–242CrossRefPubMedGoogle Scholar
  17. 17.
    Yerram P, Chaudhary K (2014) Calcific uremic arteriolopathy in end stage renal disease: pathophysiology and management. The Ochsner Journal 14:380–385PubMedCentralPubMedGoogle Scholar
  18. 18.
    Nigwekar SU, Brunelli SM, Meade D et al (2013) Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol 8:1162–1170PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Baldwin C, Farah M, Leung M et al (2011). Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis 58:988–991CrossRefPubMedGoogle Scholar
  20. 20.
    National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1–S201Google Scholar
  21. 21.
    KDIGO (2009) Treatment of CKD–MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int 76(Suppl 113):S50–S69Google Scholar
  22. 22.
    Fouque D, Horne R, Cozzolino M, Kalantar-Zadeh K (2014) Balancing nutrition and serum phosphorus in maintenance dialysis. Am J Kidney Dis 64:143–150CrossRefPubMedGoogle Scholar
  23. 23.
    Goto S, Nakai K, Kono K et al (2014) Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advancedstage chronic kidney disease. Clin Exp Nephrol 18:925–931CrossRefPubMedGoogle Scholar
  24. 24.
    Cianciaruso B, Pota A, Bellizzi V et al (2009) Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial. Am J Kidney Dis 54:1052–1061CrossRefPubMedGoogle Scholar
  25. 25.
    Aparicio M, Bellizzi V, Chauveau P et al (2012) Protein-restricted diets plus keto/amino acids–a valid therapeutic approach for chronic kidney disease patients J Ren Nutr 22(2 Suppl):S1–S21CrossRefPubMedGoogle Scholar
  26. 26.
    Jeffery EH, Abreo K, Burgess E et al (1996) Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. J Toxicol Environ Health 48:649–665CrossRefPubMedGoogle Scholar
  27. 27.
    Russo D, Miranda I, Ruocco C et al (2007) The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72:1255–1261CrossRefPubMedGoogle Scholar
  28. 28.
    Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252CrossRefPubMedGoogle Scholar
  29. 29.
    Block GA, Spiegel DM, Ehrlich J et al (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68:1815–1824CrossRefPubMedGoogle Scholar
  30. 30.
    Qunibi W, Moustafa M, Muenz LR et al (2008) A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51:952–965CrossRefPubMedGoogle Scholar
  31. 31.
    Barreto D V, Barreto Fde C, de Carvalho AB et al (2008) Phosphate binder impact on bone remodeling and coronary calcification–results from the BRiC study. Nephron Clin Pract 110:c273–c283CrossRefPubMedGoogle Scholar
  32. 32.
    Di Iorio B, Molony D, Bell C et al (2013) Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62:771–778CrossRefPubMedGoogle Scholar
  33. 33.
    Galassi A, Bellasi A, Auricchio S et al (2013) Which vitamin D in CKD-BD? The time of burning questions. Biomed Res Int 2013:864012. doi:10.1155/2013/864012PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Cheng J, Zhang W, Zhang X et al (2012) Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 7:391–400CrossRefPubMedGoogle Scholar
  35. 35.
    Brown EM, Gamba G, Riccardi D et al (1993) Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575–580CrossRefPubMedGoogle Scholar
  36. 36.
    Block GA, Martin KJ, de Francisco AL et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525CrossRefPubMedGoogle Scholar
  37. 37.
    Lindberg JS, Culleton B, Wong G et al (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16:800–807CrossRefPubMedGoogle Scholar
  38. 38.
    Moe SM, Chertow GM, Coburn JW et al (2005) Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67:760–771CrossRefPubMedGoogle Scholar
  39. 39.
    Fukuda N, Tanaka H, Tominaga Y et al (1993) Decreased 1,25 dihydroxyvitamin D3 receptor density is associated with a more severe form of pathyroid hyperplasia in chronic uremic patients J Clin Invest 92:1436–1439PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Yano S, Sugimoto T, Tsukamoto T et al (2000) Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism Kidney Int 58:1980–1986CrossRefPubMedGoogle Scholar
  41. 41.
    Komaba H, Fukagawa M (2010) FGF23-parathyroid interaction: implication in chronic kidney disease. Kidney Int 77:292–298CrossRefPubMedGoogle Scholar
  42. 42.
    Messa P, Sindici C, Cannella G et al (1998) Persistent hyperparathyroidism after renal transplantation. Kidney Int 54:1704–1713CrossRefPubMedGoogle Scholar
  43. 43.
    Bertoni E, Rosati A, Larti A et al (2006) Chronic kidney disease is still present after renal transplantation with excellent function. Transplant Proc 38:1024–1025CrossRefPubMedGoogle Scholar
  44. 44.
    Gioviale MC, Bellavia M, Damiano G et al (2012) Post transplantation tertiary hyperparathyroidism. Ann Tranplant 17:111–119Google Scholar
  45. 45.
    Li MH, Inoue K, Si HF et al (2011) Calcium-permeable ion channels involved in glutamate receptor-independent ischemic brain injury. Acta Pharmacol Sin 32:734–740PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Rix M, Levin E, Olgaard K (2003) Posttransplant bone disease. Transplant Rev 17:176–186CrossRefGoogle Scholar
  47. 47.
    Monier-Faugere MC, Mawad H, Qi Q et al (2000) High prevalence of low bone turnover and occurence of osteomalacia aftere kideny transplantation. J Am Soc Nephrol 11:1093–1099PubMedGoogle Scholar
  48. 48.
    Parker CR, Freemont AJ, Blackwell PJ et al (1999) Cross-sectional analysis of renal transplantation osteoporosis. Bone Miner Res 14:1943–1951CrossRefGoogle Scholar
  49. 49.
    Lewin E, Olgaard K (2006) Parathyroidectomy vs calcimimetics for treatment of persistent hyperparathyroidism after kidney transplantation. Nephrol Dial Transplant 21:1766–1769CrossRefPubMedGoogle Scholar
  50. 50.
    Cohen JB, Gordon CE, Balk EM et al (2012) Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis. Transplantation 94:1041–1048CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2016

Authors and Affiliations

  • Luigi Biancone
    • 1
  • Gianluca Leonardi
  • Massimo Gai
  • Giuseppe P. Segoloni
  1. 1.Department of Medical SciencesUniversity of TurinTurinItaly

Personalised recommendations